Almirall SA
http://www.almirall.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Almirall SA
Lilly’s Ebglyss Brings Once-Monthly Dosing To US Atopic Dermatitis Market
The IL-13 inhibitor will go up against Regeneron/Sanofi’s Dupixent. Lilly executives talked to Scrip about the US launch.
Leo Shrugs Off Timber Drug Failure As Revenues Roar
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.
2025’s Therapy Area Growth Drivers And Brakes: Part Two
The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.
Leo’s Congenital Ichthyosis Candidate Fails Phase III Study
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice